NRx Pharmaceuticals Stock (NASDAQ:NRXP)

Forecast Revenue Ownership Financials Chart Transcripts

Previous Close

$1.52

52W Range

$1.10 - $7.33

50D Avg

$1.28

200D Avg

$2.55

Market Cap

$18.14M

Avg Vol (3M)

$187.97K

Beta

1.27

Div Yield

NRXP Company Profile

NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Dec 04, 2017

Website

NRXP Performance

NRXP Financial Summary

	Dec 23	Dec 22	Dec 21
Revenue	-	-	-
Operating Income	$-27.59M	$-44.40M	$-115.80M
Net Income	$-30.15M	$-35.23M	$-71.72M
EBITDA	$-27.58M	$-44.65M	$-115.79M
Basic EPS	$-0.40	$-0.54	$-1.53
Diluted EPS	$-0.40	$-0.54	$-1.53

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts

Q3 24Nov 18, 24 | 7:51 PM

Q2 24Aug 15, 24 | 2:39 PM

Q1 24May 14, 24 | 8:11 PM

Peer Comparison

Ticker	Company
SNTI	Senti Biosciences, Inc.
LGVN	Longeveron Inc.
ADTX	Aditxt, Inc.
CING	Cingulate Inc.
NTRB	Nutriband Inc.
LEXX	Lexaria Bioscience Corp.
QNRX	Quoin Pharmaceuticals, Ltd.
VRAX	Virax Biolabs Group Limited
RNXT	RenovoRx, Inc.